The Multiple Myeloma Hub was pleased to speak with Adam Cohen, University of Pennsylvania, Philadelphia, US. We asked about the rationale for targeting FcRH5 in multiple myeloma and emerging dual-targeting strategies.
In this interview, Cohen discusses Fc receptor-homolog 5 (FcRH5) as a therapeutic target in multiple myeloma (MM) and its potential role following antigen loss associated with B-cell maturation antigen (BCMA)- or G protein-coupled receptor class C group 5 member D (GPRC5D)-directed therapy. Cohen outlines the rationale for targeting multiple antigens, the potential benefits and challenges of dual-targeting, and which patients may benefit most from these approaches. Cohen also reviews emerging data on the FcRH5-targeted bispecific antibody cevostamab, including its evaluation as monotherapy and as part of combination and sequential treatment strategies.
Intended for healthcare professionals. This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
","author_name":"Scientific Education Support"}